Nicox S.A. 2016 IR
The report details Nicox SA's activities and financial results for the fiscal year 2016, highlighting its strategic shift to refocus on its core business of research and development. Key events included the transfer of its European and international commercial operations to VISUfarma, a newly formed company created by GHO Capital, for a value of up to €26 million. The company advanced its ophthalmic product pipeline, notably resubmitting New Drug Applications to the US FDA for latanoprostene bunod (Vyzulta) and ZERVIATE (AC-170). Financially, Nicox recorded an operating loss of €7.8 million and ended the year with €28.9 million in cash and cash equivalents.
Company: Nicox S.A.
Sector: Professional & technical services
Country: France
Year: 2016
Type: IR
Pages: 179
Back to company
Nicox S.A.
Registration Document
The report details Nicox SA's activities and financial results for the fiscal year 2016, highlighting its strategic shift to refocus on its core business of research and development. Key events included the transfer of its European and international commercial operations to VISUfarma, a newly formed company created by GHO Capital, for a value of up to €26 million. The company advanced its ophthalmic product pipeline, notably resubmitting New Drug Applications to the US FDA for latanoprostene bunod (Vyzulta) and ZERVIATE (AC-170). Financially, Nicox recorded an operating loss of €7.8 million and ended the year with €28.9 million in cash and cash equivalents.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Mar 29, 2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees